-
Something wrong with this record ?
Ovulation stimulation protocols utilizing GnRH-antagonist/hCG, promote cytotoxic cell populations, predominant in patients with embryo implantation complications
J. Svoboda, Z. Ruzickova, L. Cuchalova, M. Kralickova, J. Rezacova, M. Vrana, A. Fiserova, J. Richter, J. Madar,
Language English Country Sweden
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
23685425
Knihovny.cz E-resources
- MeSH
- Anovulation drug therapy immunology MeSH
- Reproductive Techniques, Assisted MeSH
- Biomarkers metabolism MeSH
- Killer Cells, Natural drug effects immunology MeSH
- Chorionic Gonadotropin administration & dosage MeSH
- T-Lymphocytes, Cytotoxic drug effects immunology MeSH
- Adult MeSH
- Gonadotropin-Releasing Hormone antagonists & inhibitors MeSH
- Embryo Implantation drug effects immunology MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Infertility, Male drug therapy immunology MeSH
- Ovulation drug effects immunology MeSH
- CD4-CD8 Ratio MeSH
- Flow Cytometry MeSH
- Pregnancy MeSH
- Infertility, Female drug therapy immunology MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE: Gonadotropin-releasing hormone (GnRH) antagonist combined with the human chorionic gonadotropin hormone (hCG) is commonly used in assisted reproduction techniques (ARTs) to induce controlled ovarian hyperstimulation (COH) and to synchronize oocyte maturation. While hCG is known to have immunomodulatory properties, we aimed to assess its effect on immunological changes, with respect to HLA-G binding receptors and embryo implantation success. DESIGN: The study involved 103 subjects, including patients undergoing COH protocols (n=66), divided on the basis of the pair's fertility disorder (FD) causes (female FD, n=29; male FD, n=37), and age matched healthy women (n=37). The relative distribution of T cell (CD3+/CD4+, CD3+/CD8+) and NK cell (CD56bright/CD16-, CD56dim/CD16+) populations was evaluated together with HLA-G ligands KIR2DL4 and LILRB1 expression by flow cytometry in the peripheral blood of all subjects, as well as in patient follicular fluids. RESULTS: Both groups of patients exhibited a significant decrease of their CD4/CD8 index, a down-modulation of LILRB1-positive CD8 T cells, and increased KIR2DL4-positive NK cell distribution, when compared to the healthy donors. We attribute these changes to the COH protocol, since the only significant change between the patient groups was in the number of cytotoxic CD56dim NK cells (elevated in the female FD group). Patients with male FD causes, having an above-average CD4/CD8 index (≥3.17) and below-average KIR2DL4+/CD56bright NK cell levels(≤13.3%), exhibited higher embryo implantation rates. CONCLUSION: The GnRH antagonist/hCG protocol promotes CD3+/CD8+ and KIR2DL4+ NK cell levels, more abundant in subjects with lower implantation rates, and thus decreases the embryotransfer success in otherwise fertile women.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031464
- 003
- CZ-PrNML
- 005
- 20131002114540.0
- 007
- ta
- 008
- 131002s2013 sw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)23685425
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Svoboda, Jan $u Department of Immunology and Gnotobiology, Institute of Microbiology, Prague, Czech Republic.
- 245 10
- $a Ovulation stimulation protocols utilizing GnRH-antagonist/hCG, promote cytotoxic cell populations, predominant in patients with embryo implantation complications / $c J. Svoboda, Z. Ruzickova, L. Cuchalova, M. Kralickova, J. Rezacova, M. Vrana, A. Fiserova, J. Richter, J. Madar,
- 520 9_
- $a OBJECTIVE: Gonadotropin-releasing hormone (GnRH) antagonist combined with the human chorionic gonadotropin hormone (hCG) is commonly used in assisted reproduction techniques (ARTs) to induce controlled ovarian hyperstimulation (COH) and to synchronize oocyte maturation. While hCG is known to have immunomodulatory properties, we aimed to assess its effect on immunological changes, with respect to HLA-G binding receptors and embryo implantation success. DESIGN: The study involved 103 subjects, including patients undergoing COH protocols (n=66), divided on the basis of the pair's fertility disorder (FD) causes (female FD, n=29; male FD, n=37), and age matched healthy women (n=37). The relative distribution of T cell (CD3+/CD4+, CD3+/CD8+) and NK cell (CD56bright/CD16-, CD56dim/CD16+) populations was evaluated together with HLA-G ligands KIR2DL4 and LILRB1 expression by flow cytometry in the peripheral blood of all subjects, as well as in patient follicular fluids. RESULTS: Both groups of patients exhibited a significant decrease of their CD4/CD8 index, a down-modulation of LILRB1-positive CD8 T cells, and increased KIR2DL4-positive NK cell distribution, when compared to the healthy donors. We attribute these changes to the COH protocol, since the only significant change between the patient groups was in the number of cytotoxic CD56dim NK cells (elevated in the female FD group). Patients with male FD causes, having an above-average CD4/CD8 index (≥3.17) and below-average KIR2DL4+/CD56bright NK cell levels(≤13.3%), exhibited higher embryo implantation rates. CONCLUSION: The GnRH antagonist/hCG protocol promotes CD3+/CD8+ and KIR2DL4+ NK cell levels, more abundant in subjects with lower implantation rates, and thus decreases the embryotransfer success in otherwise fertile women.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a anovulace $x farmakoterapie $x imunologie $7 D000858
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a poměr CD4 a CD8 lymfocytů $7 D016516
- 650 _2
- $a choriogonadotropin $x aplikace a dávkování $7 D006063
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a implantace embrya $x účinky léků $x imunologie $7 D010064
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a hormon uvolňující gonadotropiny $x antagonisté a inhibitory $7 D007987
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženská infertilita $x farmakoterapie $x imunologie $7 D007247
- 650 _2
- $a mužská infertilita $x farmakoterapie $x imunologie $7 D007248
- 650 _2
- $a buňky NK $x účinky léků $x imunologie $7 D007694
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ovulace $x účinky léků $x imunologie $7 D010060
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a asistovaná reprodukce $7 D027724
- 650 _2
- $a cytotoxické T-lymfocyty $x účinky léků $x imunologie $7 D013602
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ruzickova, Zaneta $u -
- 700 1_
- $a Cuchalova, Lucie $u -
- 700 1_
- $a Kralickova, Milena $u -
- 700 1_
- $a Rezacova, Jitka $u -
- 700 1_
- $a Vrana, Milena $u -
- 700 1_
- $a Fiserova, Anna $u -
- 700 1_
- $a Richter, Jan $u -
- 700 1_
- $a Madar, Jindrich $u -
- 773 0_
- $w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 34, č. 3 (2013), s. 249-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23685425 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131002115057 $b ABA008
- 999 __
- $a ok $b bmc $g 995551 $s 829909
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 34 $c 3 $d 249-7 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- LZP __
- $a Pubmed-20131002